Multiple endogenous immune, stromal, and parenchymal signaling pathways

The term 'Multiple endogenous immune, stromal, and parenchymal signaling pathways' refers to a broad collection of biological communication networks rather than a single, discrete molecular target. This phrase is frequently used in clinical and regulatory literature to describe the pleiotropic mechanism of action of anti-fibrotic drugs like nintedanib, which target various receptors including PDGFR, FGFR, and VEGFR across different cell types (Wollin et al., 2015, European Respiratory Journal). These pathways are critical in the pathogenesis of fibrotic diseases, where they drive the activation of fibroblasts, the recruitment of immune cells, and the dysfunction of parenchymal cells. Because the term encompasses a wide array of distinct proteins and signaling cascades, it does not meet the criteria for a specific, canonical therapeutic target. Instead, it serves as a conceptual framework for understanding how multi-target inhibitors address the complexity of diseases like idiopathic pulmonary fibrosis (Richeldi et al., 2014, New England Journal of Medicine). Consequently, it is classified as an incorrect or overly broad target designation for structured pharmacological databases. Analysts should refer to the specific kinases and receptors involved for precise molecular characterization.

Other names

Immune, stromal, and parenchymal signalingMulti-pathway fibrotic signaling

Inhibition of multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases involved in fibrotic and inflammatory signaling cascades.